[@thegiantsshoulder] Meet The Most Important Man Alive In The History of MDMA

Link: https://youtu.be/mBy-UgSvdvg

Duration: 73 min

Transcript: Download plain text

Short Summary

Rick Doblin, founder of MAPS (Multidisciplinary Association for Psychedelic Studies), discusses his four-decade push to turn MDMA into an FDA-approved medicine for PTSD, including the only two completed Phase 3 trials published in Nature Medicine that showed roughly two-thirds of MDMA-treated participants no longer meeting PTSD criteria versus 32% on therapy alone. The wide-ranging interview covers MDMA's underground therapeutic history, his legal battles against the DEA, the August 2024 FDA rejection, and a new "net zero trauma by 2070" vision while highlighting veterans' suicide statistics and harsh federal sentencing disparities.</short>

Key Quotes

1. "But he said the real problem with humanity is that we have paleolithic emotions with medieval institutions with god-like technologies." (00:06:22)
2. "What we showed is that 32% of the people who had therapy without any MDMA at the two-month follow-up no longer had PTSD. But when you add MDMA, now it's 2/3 no longer had PTSD. It's twice as good." (00:01:17)
3. "So, the first criminalization of MDMA was itself illegal." (00:53:05)
4. "We taxed the ecstasy dealers. They donated 20,000 pills and they gave me 19,000 at $3 a dose when it was selling for like $8 a dose." (00:00:08)
5. "the VA spent 6 years, they um tested about 914 veterans with either cognitive processing therapy or prolonged exposure. And what they showed was shocking, which was half the people dropped out of the study because the therapy was too re-traumatizing." (01:01:11)

Detailed Summary

Rick Doblin's Background and MAPS Founding

Rick Doblin has spent more than four decades working to turn MDMA into an FDA-approved medicine, a mission that began in his youth and culminated in founding the nonprofit psychedelic pharmaceutical company MAPS. His path was shaped by early encounters with psychedelic pioneers and an explicit strategy to challenge drug prohibition from within the system.

• Rick Doblin was born in 1953 and committed to a psychedelic focus in 1972 after meeting Stanislav Grof and reading Realms of the Human Unconscious, dropping out of his freshman year of college to pursue LSD research.
• He returned to college in 1982 at New College, attended Esalen workshops with Stan and Christina Grof, and learned about MDMA from Debbie Harlow at Esalen before eventually connecting with Sasha Shulgin through Laura Huxley.
• Doblin earned a Harvard PhD in public policy to challenge drug prohibition from within the system, and on April 8, 1986, founded MAPS as a nonprofit psychedelic pharmaceutical company to move MDMA through the regulatory pathway.
• He funded early MAPS work by taxing legal ecstasy dealers, acquiring 19,000 pills at $3 each versus an $8 street price, using profits for 28-day toxicity studies in dogs and rats and to sue the DEA.

Phase 3 MDMA-Assisted Therapy Trials for PTSD

MAPS ran the only two completed Phase 3 MDMA-assisted therapy trials for severe PTSD in history, both published in Nature Medicine, producing the strongest efficacy data in the field. These results form the central evidentiary core of Doblin's push for FDA approval.

• In the first trial, 32% of participants who received therapy without MDMA no longer had PTSD at the two-month follow-up, compared with roughly two-thirds (~67%) when MDMA was added, with an additional 21% achieving clinically significant symptom reductions for an overall 88% response rate and 12% non-response rate—described as twice as effective as therapy alone.
• The second Phase 3 study shifted enrollment to moderate-to-severe PTSD (3/4 severe, 1/4 moderate) to avoid FDA limiting approval to severe PTSD; therapy alone produced a 47.6% no-PTSD rate, rising to about 72% no-PTSD plus another 15% clinically significant when MDMA was added, with a 1-in-10,000 chance the result was due to random factors.
• The treatment protocol requires 42 hours of therapy: three 8-hour MDMA dosing sessions plus twelve 90-minute non-drug psychotherapy sessions (three preparation and three integration sessions around each dosing day), typically delivered by a male-female co-therapy team.
• Effect sizes for the MDMA trials were very large, contrasted with SSRIs which Doblin described as barely effective with very small effect sizes.
• The VA spent six years testing about 914 veterans with prolonged exposure or cognitive processing therapy, and about half of participants dropped out because the therapy was too re-traumatizing—the two main non-drug PTSD therapies used by the VA.

MDMA's Underground Therapeutic History

Before its criminalization, MDMA had a substantial underground therapeutic history involving hundreds of clinicians and an estimated half-million doses administered before public/party use attracted government attention. This pre-ban history is central to Doblin's argument that MDMA's medical value was recognized long before regulation intervened.

• MDMA was originally synthesized by Merck pharmaceutical company in 1912; the patents later expired and it was never tested in humans by Merck.
• Sasha Shulgin worked at Dow in the early 1960s where he developed the first biodegradable insecticide, left after Dow objected to his interest in psychedelics, and set up a home lab at Shulgin Farm about 30–45 minutes from Oakland in the East Bay where he invented hundreds of psychedelics.
• Shulgin documented his work in PIHKAL and TIHKAL and tested new compounds first on himself, then with his wife Ann, then with a group of about 12 people.
• Leo Zeff, a clinical psychology PhD known as "the secret chief," tried MDMA in the 1970s and decided not to retire because he found it so effective; MDMA was used as therapy under the code name "Adam" starting around 1976 by Shulgin, Zeff, and hundreds of other psychiatrists and therapists.
• By the early 1980s, approximately half a million doses of MDMA had been used in private therapeutic and personal-growth contexts before the government focused on its public/party use as ecstasy.

DEA Battles and Criminalization

Doblin's path to FDA approval has been repeatedly obstructed by DEA actions dating back to the mid-1980s, requiring multiple lawsuits and legal maneuvering to delay or challenge criminalization. These early battles established the legal precedent that continues to shape MDMA's status today.

• In summer 1984, the DEA announced plans to criminalize MDMA via a Federal Register notice with a 30-day public comment period; Doblin worked with pro bono lawyers from a large DC firm and sued, delaying criminalization by about a year.
• After losing in US courts, the DEA pushed to criminalize MDMA internationally through the World Health Organization in Geneva in 1985, which Doblin traveled to oppose.
• The DEA conducted an emergency scheduling of MDMA in summer 1985; after hearings, the judge ruled MDMA should remain Schedule III as a medicine and illegal for recreational use, but the DEA administrator refused to follow the ruling.
• Doblin's group sued the DEA twice in appeals courts and won both times; only on a third DEA attempt did the agency find a way to satisfy the court and keep MDMA illegal.
• The DEA's 1985 emergency scheduling was itself illegal because the Attorney General had never subdelegated scheduling authority to the DEA, so everyone arrested between 1985 and 1986 for MDMA-related offenses was freed once lawyers identified the procedural flaw.

Regulatory Landscape and Political Context

The FDA's August 2024 rejection of MDMA marked a major setback, but political dynamics have shifted significantly with a White House executive order in 2026 aimed at promoting psychedelics development. Doblin frames the regulatory friction as part of a broader pattern in which major societal decisions are driven by emotion rather than data.

• In August 2024, the FDA rejected approval of MDMA, with one cited reason being the agency's failure to understand the therapy component of the treatment, and another being the failure to formally log euphoria as a data point.
• Doblin frames the FDA's euphoria concern as a regulatory fear that participants who enjoyed the drug during a trial would abuse it afterward; he argues MDMA has a built-in anti-addiction mechanism because repeated use builds tolerance so that raising the dose yields speedy but not "open-hearted" effects, with overall effects diminishing over time, unlike cocaine, methamphetamine, and opiates.
• After 40+ years of recreational MDMA use, Doblin states he does not see ecstasy addicts; some heavy users engage frequently for about a year and then burn out.
• On April 18, 2026, President Trump issued a White House executive order to promote psychedelics development, influenced in part by a message Joe Rogan sent to Trump.
• A roughly 45-minute Oval Office signing ceremony video shows Joe Rogan explaining to Trump that psychedelics were criminalized in 1970 not because of harm but because Nixon's main enemies were the civil rights movement and the hippies, and Nixon criminalized their drugs to disrupt their political work.
• Doblin testified before the US Sentencing Commission in 2001 during the peak of MDMA neurotoxicity fears, and states that federal sentencing guidelines have not been reviewed in 25 years, so equivalent weights of MDMA currently trigger harsher sentences than cocaine.

Veterans, Suicide, and the "Net Zero Trauma" Vision

A core motivation for Doblin's work is the scale of veteran PTSD and suicide, which has grown dramatically since MAPS was founded in 1986. He has articulated a long-term vision—"net zero trauma by 2070"—aimed at halting and eventually reversing both experienced and inherited trauma.

• The VA pays over $17 billion a year in disability costs, and when MAPS began in 1986, over 200,000 US veterans were on disability for Vietnam War PTSD at about $4.3 billion per year, compared with over a million veterans disabled with PTSD today.
• Since 2001, about 10,000 US soldiers have died in Iraq and Afghanistan, while more than 10 times that number have died by suicide; approximately 6,000 veterans kill themselves each year, with another 25,000–30,000 non-veteran Americans dying by suicide annually.
• Bill W, the founder of Alcoholics Anonymous, took LSD in the 1950s and believed it had a major role in treating addiction.
• Doblin introduced "net zero trauma by 2070," a vision to stop adding to the global burden of trauma and eventually reduce it, including experienced trauma and inherited multi-generational trauma via epigenetic mechanisms.

Broader Cultural Framing

Doblin situates psychedelic medicine within a larger civilizational argument about the mismatch between human emotional evolution and technological power. He positions MDMA specifically as the gentlest and most therapeutically tractable psychedelic compound.

• Doblin cites Harvard scientist E.O. Wilson's framing that humanity's real problem is having "paleolithic emotions, medieval institutions, and god-like technologies" to justify accelerating emotional and spiritual development through psychedelics.
• He invokes Albert Einstein's aphorism that splitting the atom changed everything except our mode of thinking, and frames the needed "whole new mode of thinking" as a merger of rationality with experiential, transpersonal/humanistic psychology—what he calls "psychedelic thinking."
• Doblin states MDMA was chosen over other psychedelics because it is the most gentle, does not produce ego dissolution like classic psychedelics, and promotes safety, love, compassion, and oxytocin release.
• MAPS has raised approximately $160 million in donations over time, while $5–6 billion has been invested in for-profit psychedelic companies since 2018, including about $200 million raised into a for-profit psychedelic company that has since separated from MAPS with new management committed to keeping MDMA generic and inexpensive in Africa, India, Lebanon, and other low/middle-income countries.
• Doblin states MDMA's approval as a medicine is on track for this year or next year, aided by the Trump executive order.

Notable Clarifications and Disagreements

Throughout the interview, Doblin corrected several common misconceptions and pushed back against the host's assumptions about how regulatory bodies should respond to strong efficacy data. These exchanges reveal the gap between evidentiary logic and institutional behavior.

• The claim that Sasha Shulgin's lab was built underneath a volcano is false; that story refers to Leonard Pickard, an LSD manufacturer who operated in a missile silo.
• Dealers claiming to sell "MAPS MDMA" as the purest form on the street is a marketing lie; MAPS MDMA is legal, under DEA control, and none has ever escaped to the street.
• When the host argues the strong MDMA-for-PTSD data should logically trigger fast-track FDA approval, Doblin counters that major societal decisions are driven by emotion, fear, and the designation of common enemies rather than data, pointing to the election of Donald Trump as evidence of irrational drivers overriding facts.